Mp06-16 Long-Term Outcomes After Urethral Stricture Treatment With the Optilume® Urethral Drug Coated Balloon: 5 Year Results From the Robust I Study

You have accessJournal of UrologyReconstruction: Urethral Reconstruction (including stricture) I (MP06)1 May 2024MP06-16 LONG-TERM OUTCOMES AFTER URETHRAL STRICTURE TREATMENT WITH THE OPTILUME® URETHRAL DRUG COATED BALLOON: 5 YEAR RESULTS FROM THE ROBUST I STUDY Jessica DeLong, Sean Elliott, Ramon Virasoro, Merycarla Pichardo, Rafael Estrella, Ramon Rodriguez Lay, and Gustavo Espino Jessica DeLongJessica DeLong , Sean ElliottSean Elliott , Ramon VirasoroRamon Virasoro , Merycarla PichardoMerycarla Pichardo , Rafael EstrellaRafael Estrella , Ramon Rodriguez LayRamon Rodriguez Lay , and Gustavo EspinoGustavo Espino View All Author Informationhttps://doi.org/10.1097/01.JU.0001009452.79331.fd.16AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Urethral dilation and internal urethrotomy are the most common treatments for urethral stricture, but recurrence rates approach 100% after repeat endoscopic treatments. Long-term outcomes of recurrent strictures treated with the Optilume Urethral Drug Coated Balloon (DCB) are reported here. METHODS: Men with recurrent bulbar stricture ≤ 2cm with 1-4 prior endoscopic treatments were treated with the Optilume Urethral DCB. Primary safety endpoint was serious urinary adverse events. Primary efficacy endpoint was the proportion of subjects with≥50% improvement in IPSS at 5 years. Subjects receiving secondary treatment were treated as failures for this endpoint. Secondary outcomes included QoL, freedom from repeat intervention, erectile function, flow rate, and PVR. RESULTS: 53 subjects were enrolled; 43 were evaluable at 5 year follow-up. 43% of men had≥2 previous dilations with a mean of 1.7 prior dilations. No reported serious adverse events related to treatment at 5 years. Success was achieved in 25/43 (58.1%). IPSS improved from a mean of 25.2 at baseline to 7.2 at 5 years (p<0.001). Freedom from repeat intervention rate was 29/43 (67%). QoL, flow rate, and PVR improved significantly from baseline. No impact on erectile function was reported. CONCLUSIONS: Subjects treated with the Optilume Urethral DCB exhibited significant improvement in symptomatic and functional outcomes through 5 years posttreatment. Symptomatic response to treatment remained stable from 2 to 5 years post-treatment. The Optilume Urethral DCB represents a safe and durable treatment option for patients with recurrent bulbar stricture. Source of Funding: Laborie © 2024 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 211Issue 5SMay 2024Page: e58 Advertisement Copyright & Permissions© 2024 by American Urological Association Education and Research, Inc.Metrics Author Information Jessica DeLong More articles by this author Sean Elliott More articles by this author Ramon Virasoro More articles by this author Merycarla Pichardo More articles by this author Rafael Estrella More articles by this author Ramon Rodriguez Lay More articles by this author Gustavo Espino More articles by this author Expand All Advertisement PDF downloadLoading ...